Cerus Corporation (CERS)
US — Healthcare Sector
Automate Your Wheel Strategy on CERS
With Tiblio's Option Bot, you can configure your own wheel strategy including CERS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CERS
- Rev/Share 0.9897
- Book/Share 0.3007
- PB 4.5846
- Debt/Equity 1.7921
- CurrentRatio 2.3176
- ROIC -0.1128
- MktCap 259977600.0
- FreeCF/Share 0.0358
- PFCF 38.7679
- PE -13.4274
- Debt/Assets 0.4809
- DivYield 0
- ROE -0.3531
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript
CERS
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Cerus Corporation (NASDAQ:CERS ) Q4 2024 Earnings Call February 20, 2025 4:30 PM ET Company Participants Noopur Liffick - Investor Relations Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President Conference Call Participants Joshua Jennings - TD Cowen Jacob Johnson - Stephens. Ross Osborn - Cantor Fitzgerald John Wilkin - Craig-Hallum Operator Good day, ladies and gentlemen.
Read More
About Cerus Corporation (CERS)
- IPO Date 1997-01-31
- Website https://www.cerus.com
- Industry Medical - Devices
- CEO William M. Greenman
- Employees 614
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.